Spencer Ryan — SEC Form 4 filings
SEC reporting owner CIK 1777938. 12 Form 4 filings on record with FilingPulse; latest filed 2026-02-10.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-02-06 to 2026-02-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 48.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| DYNAVAX TECHNOLOGIES CORP (DVAX) | CEO and Director, Director | 8 | — | — | 42 |
| Cidara Therapeutics, Inc. (CDTX) | Director | 4 | — | — | 6 |
Form 4 filings — Spencer Ryan
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-10 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) | Code (U): 379,620 · Grant/award (A): 165,000 · Disposition to issuer (D): 165,000 · Grant/award (A): 136,000 · Disposition to issuer (D): 136,000 · Disposition to issuer (D): 50,000 (derivative) · +9 more | EDGAR |
| 2026-01-07 | 4 | Cidara Therapeutics, Inc. (CDTX) | Disposition to issuer (D): 4,250 (derivative) · Disposition to issuer (D): 2,125 (derivative) · Disposition to issuer (D): 11,100 (derivative) | EDGAR |
| 2025-12-29 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) | Grant/award (A): 156,250 · Option exercise (M): 55,000 · Option exercise (M): 45,333 · Tax withholding (F): 138,168 @ $15.38 · Option exercise (M): 55,000 (derivative) · Option exercise (M): 45,333 (derivative) | EDGAR |
| 2025-06-18 | 4 | Cidara Therapeutics, Inc. (CDTX) | Grant/award (A): 11,100 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) | Option exercise (M): 55,000 · Tax withholding (F): 36,528 @ $12.93 · Option exercise (M): 55,000 (derivative) | EDGAR |
| 2025-02-18 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) | Option exercise (M): 62,500 · Tax withholding (F): 31,694 @ $12.69 · Grant/award (A): 62,500 (derivative) · Option exercise (M): 62,500 (derivative) · Grant/award (A): 225,000 (derivative) · Grant/award (A): 136,000 (derivative) | EDGAR |
| 2025-02-12 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) | Option exercise (M): 20,833 · Tax withholding (F): 11,209 @ $13.20 · Option exercise (M): 20,833 (derivative) | EDGAR |
| 2024-07-19 | 4 | Cidara Therapeutics, Inc. (CDTX) | Grant/award (A): 2,125 (derivative) @ $0 | EDGAR |
| 2024-04-30 | 4 | Cidara Therapeutics, Inc. (CDTX) | Grant/award (A): 4,250 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) | Grant/award (A): 402 @ $9.45 · Grant/award (A): 231,000 (derivative) @ $0 · Grant/award (A): 165,000 (derivative) | EDGAR |
| 2024-02-13 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) | Option exercise (M): 20,833 · Tax withholding (F): 11,684 @ $12.82 · Option exercise (M): 20,833 (derivative) | EDGAR |
| 2024-02-06 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) | Option exercise (M): 29,750 · Tax withholding (F): 17,129 @ $12.79 · Option exercise (M): 29,750 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1777938 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →